This is a preview of subscription content, log in via an institution to check access.
References and Recommended Reading
Burke JF, Mogg AE: Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985, 13:6265–6272.
Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999, 104:375–381.
Wilschanski M, Famini C, Blau H, et al.: A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000, 161:860–865.
Clancy JP, Bebok Z, Ruiz F, et al.: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:1683–1692.
Karpati G, Lochmuller H: When running a stop sign may be a good thing. Ann Neurol 2001, 49:693–694.
Rights and permissions
About this article
Cite this article
Hirano, M. Aminoglycoside treatment for muscular dystrophy is scientifically rational, but is it clinically effective?. Curr Neurol Neurosci Rep 2, 53–54 (2002). https://doi.org/10.1007/s11910-002-0053-y
Issue Date:
DOI: https://doi.org/10.1007/s11910-002-0053-y